Merck & Co will pay NGM Biopharmaceuticals $96m up front and spend $106m to own a 15% share of the privately-held company and the big pharma will provide at least $250m during the next five to fund research and development through Phase II for novel biologics across a wide range of diseases.
The transaction gives Merck an initial license for NP201, a preclinical candidate for the treatment of diabetes, obesity and non-alcoholic...
Welcome to Scrip
Create an account to read this article
Already a subscriber?